FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2980147477> ?p ?o ?g. }

• W2980147477 abstract "Abstract Abstract 5059 JAK2 inhibitors are known to improve symptoms, to control myeloproliferation and to reduce splenomegaly in patients diagnosed with chronic myeloproliferative neoplasms (MPNs)Ph(-). However their ability to decrease the allele burden and achieve molecular responses is controversial. Objective: To evaluate hematologic, clinical and molecular responses according to the criteria of the European LeukemiaNet and European Myelofibrosis Network in 13 patients treated with JAK2 inhibitors. Material and Methods: We performed a prospective study in the Haematology Service of the Hospital La Pazbetween 1987 and 2012 in 13 patients diagnosed with NMP Ph (-) and treated with of JAK2 inhibitors: 5 secondary mylofibrosis (SFM)to homozygous polycythemia vera JAK (+), 4 SFM to essential thrombocythemias JAK (-), 2 primary myelofibrosis (one JAK (-) and one heterozygous JAK (+)) and 2 homozygous PV JAK (+) resistant to hydrea. The RT-PCR was performed at 6 or 12 months after the first determination of the allelic burden. Median follow-up was 3 months (1 – 15). A) Hematologic Response (HR): 3/5 SFM to PV(1)/TE JAK(-)(2) reached HR at 3 months of initiation of JAK2 inhibitor to 20mg/day. Molecular and clinical response were not evaluated. B) Clinical Response: Three patients had a reduction in the spleen size. Only one patient in the SFM group had a reduction in the spleen size (18 cm before the drug was commenced to 13. 7 cm) and the allele burden decrease from 55% to 23% after 5 months of therapy with JAK2 inhibitor at 25mg/12h (increase of 5mg/12h after 15 days of initiation of medication). 2/3 MFS to TE JAK(-) had a reduction from 15, 3 cm before the drug was commenced to 9 cm after 3 months of therapy with JAK2 inhibitor at 20 mg/12h. 3/3 MFP JAK(-) had a 6cm reduction in spleen size. Twenty cm splenomegaly was documented before starting JAK2 inhibitor to 15 mg/day. C) Molecular Response: 2/5 SFM to PV decreased the previous allele burden value. One patient decreased by 25% the previous allele burden value (99. 28%) at 6 months of JAK2 inhibitor. Second patient decreased by 13% the previous allele burden value (55%) at 6 months of starting JAK2 inhibitor to 25 mg/day. In 1/2 PV, the previous allele burden value (93. 17%) decreased by 11. 4% at 6 months of starting JAK2 inhibitor at 100mg/24h. D) Lack of response and disease progression: One patient with SMF secondary to JAK 2 (-) ET had dose reductions from 20 mg twice a day secondary to grade IV thrombocytopenia and renal toxicity. Patient finally developed acute leukemia. Conclusions: Our study confirms that JAK2 inhibitors reduce splenomegaly in MPNs JAK(-)and JAK(+). Prospective studies with an adequate sample size are necessary to demonstrate whether splenomegaly and symptom reductions achieved with inhibition of JAK2 could be associated to decrease the allele burden and achieve molecular responses in MPNs JAK(+). Disclosures: No relevant conflicts of interest to declare." @default.
• W2980147477 created "2019-10-18" @default.
• W2980147477 creator A5002936841 @default.
• W2980147477 creator A5012901520 @default.
• W2980147477 creator A5021032009 @default.
• W2980147477 creator A5025126361 @default.
• W2980147477 creator A5056776192 @default.
• W2980147477 date "2012-11-16" @default.
• W2980147477 modified "2023-10-01" @default.
• W2980147477 title "JAK2 Inhibitor Therapy in Chronic Myeloproliferative Neoplasms Ph(-): Hematologic, Clinical and Molecular Responses" @default.
• W2980147477 doi "https://doi.org/10.1182/blood.v120.21.5059.5059" @default.
• W2980147477 hasPublicationYear "2012" @default.
• W2980147477 type Work @default.
• W2980147477 sameAs 2980147477 @default.
• W2980147477 citedByCount "0" @default.
• W2980147477 crossrefType "journal-article" @default.
• W2980147477 hasAuthorship W2980147477A5002936841 @default.
• W2980147477 hasAuthorship W2980147477A5012901520 @default.
• W2980147477 hasAuthorship W2980147477A5021032009 @default.
• W2980147477 hasAuthorship W2980147477A5025126361 @default.
• W2980147477 hasAuthorship W2980147477A5056776192 @default.
• W2980147477 hasConcept C126322002 @default.
• W2980147477 hasConcept C194409129 @default.
• W2980147477 hasConcept C2776112149 @default.
• W2980147477 hasConcept C2778837598 @default.
• W2980147477 hasConcept C2780007613 @default.
• W2980147477 hasConcept C2780076729 @default.
• W2980147477 hasConcept C2781057849 @default.
• W2980147477 hasConcept C71924100 @default.
• W2980147477 hasConcept C90924648 @default.
• W2980147477 hasConceptScore W2980147477C126322002 @default.
• W2980147477 hasConceptScore W2980147477C194409129 @default.
• W2980147477 hasConceptScore W2980147477C2776112149 @default.
• W2980147477 hasConceptScore W2980147477C2778837598 @default.
• W2980147477 hasConceptScore W2980147477C2780007613 @default.
• W2980147477 hasConceptScore W2980147477C2780076729 @default.
• W2980147477 hasConceptScore W2980147477C2781057849 @default.
• W2980147477 hasConceptScore W2980147477C71924100 @default.
• W2980147477 hasConceptScore W2980147477C90924648 @default.
• W2980147477 hasLocation W29801474771 @default.
• W2980147477 hasOpenAccess W2980147477 @default.
• W2980147477 hasPrimaryLocation W29801474771 @default.
• W2980147477 hasRelatedWork W2012828222 @default.
• W2980147477 hasRelatedWork W2013238178 @default.
• W2980147477 hasRelatedWork W2048488970 @default.
• W2980147477 hasRelatedWork W2086740979 @default.
• W2980147477 hasRelatedWork W2090833261 @default.
• W2980147477 hasRelatedWork W2091949363 @default.
• W2980147477 hasRelatedWork W2157874509 @default.
• W2980147477 hasRelatedWork W2310252693 @default.
• W2980147477 hasRelatedWork W2462280137 @default.
• W2980147477 hasRelatedWork W2558450558 @default.
• W2980147477 hasRelatedWork W2559167331 @default.
• W2980147477 hasRelatedWork W2562725367 @default.
• W2980147477 hasRelatedWork W2577901327 @default.
• W2980147477 hasRelatedWork W2591218753 @default.
• W2980147477 hasRelatedWork W2617895748 @default.
• W2980147477 hasRelatedWork W2751027104 @default.
• W2980147477 hasRelatedWork W2911429376 @default.
• W2980147477 hasRelatedWork W2913121449 @default.
• W2980147477 hasRelatedWork W2979679864 @default.
• W2980147477 hasRelatedWork W2997707101 @default.
• W2980147477 isParatext "false" @default.
• W2980147477 isRetracted "false" @default.
• W2980147477 magId "2980147477" @default.
• W2980147477 workType "article" @default.